Introduction
The culmination of sustained lower oil prices, fear of an imminent rate hike and weakness in China have indiscriminately plummeted all indices over the past week. These exogenous forces are ostensibly unrelated to the biotechnology cohort yet this group has been taken along for the downhill ride with the broader indices in lock-step. The biotechnology sector has been on an unprecedented performance streak in both annual and cumulative performance over the past 10 years and accentuated during the latest 5 year timeframe however lately this streak has been tested. The biotechnology sector can be highly volatile, however I posit that this cohort has not only established itself as a secular growth sector but these latest events are unrelated to the biotech sector and thus this recent correction may provide a unique opportunity to add to a current position or initiate a position over time as this correction unfolds. Based on annual and cumulative performance throughout both bear and bull markets, IBB (iShares Nasdaq Biotechnology) may provide the opportunity investors have been waiting for in the face of our current market conditions. IBB is down 15% from its 52-week high, shares have plunged from $400 to $340 per share during the recent market weakness, presenting a potential buying opportunity. Continue reading "Extraneous Events Providing Unique Buying Opportunity In The Biotechnology Cohort"





